Novel HMG-CoA reductase inhibitors

Claim 1

A compound represented by the following structural formula (I): ##STR18## wherein: R is CH 2 OH, ##STR19## or CO 2 R 4 ; R 1 and R 3 are independently selected from: (1) C 1-10 alkyl; (2) substituted C 1-10 alkyl in which one or more substituent(s) is selected from (a) halogen, (b) hydroxy, (c) C 1-10 alkoxy, (d) C 1-5 alkoxycarbonyl, (e) C 1-5 acyloxy, (f) C 3-8 cycloalkyl, (g) phenyl, (h) substituted phenyl in which the substituents are X and Y, and (i) oxo; (3) C 3-8 cycloalkyl; (4) substituted C 3-8 cycloalkyl in which one substituent is selected from (a) C 1-10 alkyl, (b) substituted C 1-10 alkyl in which the substituent is selected from (i) halogen, (ii) hydroxy, (iii) C 1-10 alkoxy (iv) C 1-5 acyloxy, (v) C 1-5 alkoxycarbonyl, (vi) phenyl, (vii) substituted phenyl in which the substituents are X and Y, and (viii) oxo, (c) halogen, (d) hydroxy, (e) C 1-10 alkoxy, (f) C 1-5 alkoxycarbonyl, (g) C 1-5 acyloxy, (h) phenyl, (i) substituted phenyl in which the substituents are X and Y; (5) phenylamino; (6) substituted phenylamino in which the substituents are X and Y; (7) phenyl C 1-10 alkylamino; and (8) substituted phenyl C 1-10 alkylamino in which the substituents are X and Y. R 4 is independently selected from (a) hydrogen; (b) C 1-5 alkyl; (c) substituted-C 1-5 alkyl in which the substituent is selected from (i) phenyl, (ii) dimethylamino, and (iii) acetylamino; and (d) 2,3-dihydroxypropyl; X and Y independently are hydrogen, halogen, trifluoromethyl, C 1-3 alkyl, nitro, cyano or group selected from: (1) R 8 O(CH 2 ) m in which m is 0 to 3 and R 8 is hydrogen, C 1-3 alkyl or hydroxy-C 2-3 alkyl; (2) ##STR20## in which R 9 is hydrogen, C 1-3 alkyl, hydroxy-C 2-3 alkyl, phenyl, naphthyl, amino-C 1-3 alkyl, C 1-3 alkylamino-C 1-3 alkyl, di(C 1-3 alkyl)amino-C 1-3 alkyl, hydroxy-C 2-3 alkylamino-C 1-3 alkyl or di(hydroxy-C 2-3 alkyl) amino-C 1-3 alkyl; (3) ##STR21## in which R 10 is hydrogen, C 1 -3alkyl, hydroxy-C 2-3 alkyl, C 1-3 alkoxy-C 1-3 alkyl, phenyl or naphthyl; (4) R 11 R 12 N(CH 2 ) m , ##STR22## in which R 11 and R 12 independently are hydrogen, (5) R 13 S(0) n (CH 2 ) m in which R 13 is hydrogen, C 1-3 alkyl, amino, C 1-3 alkylamino or di(C 1-3 alkyl)amino; and a represents a single bond or a double bond; or a pharmaceutically acceptable salt thereof.